[Prospective study on using of autologous LAK cell reinfusion in the treatment of chronic hepatitis B].
The results of a prospective controlled randomized clinical study on using of autologous LAK cell reinfusion in the treatment of chronic hepatitis B (including CAH and CPH) were reported. The study was based on the criteria formulated by the National Conference of Viral Hepatitis in 1984 and patients were randomly assigned in two groups (39 cases in treated group and 25 in control group). Patients in the treated group received autologous LAK cell reinfusion treatment alone for 6 weeks and the control group 10% glucose solution intravenous drip also for 6 weeks. HBeAg seronegative rate anti-HBe seropositive rate and normalization rate of ALT after completion of the therapy were 53.8%, 28.2% and 33.3% respectively in the treated group and 20.0%, 8.0% and 4.0% respectively in the control group. The difference of parameters between the treated group and control group as described above was of statistical significance, but definite evaluation of the efficacy of this therapy can only be made after a more extended controlled randomized clinical study.
D000293:Adolescent; D000328:Adult; D005260:Female; D006509:Hepatitis B / Q000628:therapy*; D006521:Hepatitis, Chronic / Q000628:therapy*; D006801:Humans; D016219:Immunotherapy, Adoptive; D015979:Killer Cells, Lymphokine-Activated / Q000637:transplantation*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies